A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; ... ; Schellens, J.H.M. (2019)

Article / Letter to editor

• Cost-analysis
• Dihydropyrimidine dehydrogenase
• DPYD
• Pharmacogenetics
• Fluoropyrimidines
• Genotyping
• Toxicity

• All authors: Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J.; Schellens, J.H.M.
• Date: 2019-01-31
• Journal: European Journal of Cancer
• Volume: 107
• Pages: 60 - 67
• DOI: doi:10.1016/j.ejca.2018.11.010